Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice. (Q53085261)

11 May 2018

title

Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice. (English)

1 reference

11 May 2018

author name string

Ying Liu

1

1 reference

11 May 2018

Xing Luo

2

1 reference

11 May 2018

Chunting Yang

3

1 reference

11 May 2018

Sanke Yu

4

1 reference

11 May 2018

Honglin Xu

5

1 reference

11 May 2018

language of work or name

English

0 references

publication date

12 June 2011

1 reference

11 May 2018

published in

Vaccine

1 reference

11 May 2018

volume

29

1 reference

11 May 2018

issue

34

1 reference

11 May 2018

page(s)

5778-5784

1 reference

11 May 2018

Therapeutic potential of Toll-like receptor 9 activation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Immunotherapeutic uses of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

A Toll-like receptor recognizes bacterial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

CpG oligonucleotides induce strong humoral but only weak CD4+ T cell responses to protein antigens in rhesus macaques in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

CpG oligodeoxynucleotides as vaccine adjuvants in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Cutting edge: rapid in vivo killing by memory CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

TLR9 signaling in B cells determines class switch recombination to IgG2a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Cross-priming in health and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

CpG-DNA aided cross-priming by cross-presenting B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Type I interferon is required to mount an adaptive response to immunostimulatory DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Role of interferon-γ during CpG oligodeoxynucleotide-adjuvanted immunization with recombinant proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

Mechanism and function of a newly identified CpG DNA motif in human primary B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.087

10.1016/J.VACCINE.2011.05.087

7 January 2021

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

21664398

1 reference

11 May 2018